REG - BkofA Merrill Lynch Horizon Therapeutics - 20230914_HORIZON THERAPEUTICS PLC_38.5 (b)_IE_BANA

AmgenAnnouncement

15/09/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230915:nRSO6273Ma&default-theme=true

RNS Number : 6347M  Bank of America Merrill Lynch  15 September 2023

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 1.  KEY INFORMATION

 Name of exempt principal trader             Bank of America, N.A., Proprietary
 Company dealt in                            HORIZON THERAPEUTICS PLC
 Class of relevant security to which the     Common - IE00BQPVQZ61

dealings being disclosed relate(Note 1)
 Date of dealing                             14/09/2023

Bank of America, N.A., Proprietary

 Company dealt in

HORIZON THERAPEUTICS PLC

 Class of relevant security to which the

dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

 Date of dealing

14/09/2023

 

 2.  INTERESTS AND SHORT POSITIONS

 (a)  Interests and short positions (following dealing) in the class of relevant
      security

dealt in (Note 2)

 Class of relevant security: Common             IE00BQPVQZ61
                                                Long               Short
                                                Number     %       Number     %
 (1)  Relevant securities                       1,022,121  0.446%  947,306    0.414%
 (2)  Derivatives (other than options):         1,033,760  0.452%  1,026,885  0.449%
 (3)  Options and agreements to purchase/sell:  0          0%      0          0%
 Total                                          2,055,881  0.898%  1,974,191  0.863%

1,022,121

0.446%

947,306

0.414%

 (2)  Derivatives (other than options):

1,033,760

0.452%

1,026,885

0.449%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

2,055,881

0.898%

1,974,191

0.863%

 

 (b)  Interests and short positions in relevant securities of the company, other
      than the

class dealt in (Note 2)

 Class of relevant security:
                                                Long         Short
                                                Number  %    Number  %
 (1)  Relevant securities                       0       0%   0       0%
 (2)  Derivatives (other than options):         0       0%   0       0%
 (3)  Options and agreements to purchase/sell:  0       0%   0       0%
 Total                                          0       0%   0       0%

0

0%

0

0%

 (2)  Derivatives (other than options):

0

0%

0

0%

 (3)  Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

 3.  DEALINGS (Note 3)

 (a)  Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Purchase       8                              115.27 USD
 Purchase       2                              115.33 USD
 Purchase       28,100                         115.345 USD
 Purchase       133                            115.35 USD
 Purchase       3                              115.39 USD

 

 Purchase/sale  Number of relevant securities  Price per unit (Note 4)
 Sale           8                              115.27 USD
 Sale           100                            115.3 USD
 Sale           54                             115.305 USD
 Sale           27                             115.309 USD
 Sale           96                             115.31 USD
 Sale           39                             115.311 USD
 Sale           30                             115.312 USD
 Sale           45                             115.313 USD
 Sale           28                             115.32 USD
 Sale           67                             115.325 USD
 Sale           61                             115.326 USD
 Sale           26                             115.328 USD
 Sale           218                            115.33 USD
 Sale           27                             115.331 USD
 Sale           78                             115.335 USD
 Sale           35                             115.337 USD
 Sale           42                             115.338 USD
 Sale           49                             115.339 USD
 Sale           100                            115.34 USD
 Sale           118                            115.342 USD
 Sale           81                             115.343 USD
 Sale           321                            115.344 USD
 Sale           155                            115.345 USD
 Sale           164                            115.346 USD
 Sale           36                             115.347 USD
 Sale           130                            115.348 USD
 Sale           83                             115.349 USD
 Sale           962                            115.35 USD
 Sale           246                            115.351 USD
 Sale           152                            115.352 USD
 Sale           100                            115.354 USD
 Sale           58                             115.355 USD
 Sale           50                             115.357 USD
 Sale           428                            115.358 USD
 Sale           206                            115.359 USD
 Sale           600                            115.36 USD
 Sale           370                            115.361 USD
 Sale           54                             115.364 USD
 Sale           60                             115.367 USD
 Sale           26                             115.369 USD
 Sale           200                            115.37 USD
 Sale           27                             115.376 USD
 Sale           31                             115.381 USD
 Sale           34                             115.39 USD
 Sale           25                             115.397 USD

 

 (b)  Derivatives transactions (other than options transactions)

 Product name,  Nature of transaction        Number of relevant securities  Price per unit

e.g. CFD
(Note 5)                    (Note 6)
(Note 4)
 Swaps          Increasing a Short Position  28,100                         115.35 USD

 

 (c)  Options transactions in respect of existing relevant securities

 (i)  Writing, selling, purchasing or varying

 Product name, e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc  Expiry date  Option money paid/ received per unit (Note 4)
 N/A                             N/A                                         N/A                                                        N/A             N/A                                N/A          N/A

 

 (ii)  Exercising

 Product name,      Number of securities  Exercise price per

e.g. call option
unit (Note 4)
 N/A                N/A                   N/A

 

 (d)  Other dealings (including transactions in respect of new securities) (Note 3)

 Nature or transaction  Details  Price per unit
 (Note 7)
(if applicable) (Note 4)
 N/A                    N/A      N/A

 

 4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting
 rights

or future acquisition or disposal of any relevant securities to which any
 derivative

referred to on this form is referenced. If none, this should be stated.
 None

 

 Is a Supplemental Form 38.5(b) attached? (Note 8)  No

 

 Date of disclosure                            15/09/2023
 Contact name                                  Frank Lui
 Telephone number                              +44207 996 6418
 Name of offeree/offeror with which connected  AMGEN INC
 Nature of connection (Note 9)                 Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPEAENSFEXDEFA